skip to main content, skip to Quick links, or skip to Search

main content



Pilot evaluation of the efficacy and safety of caninized anti-TNF-alpha monoclonal antibody therapy to treat refractory canine atopic dermatitis in dogs


Atopic dermatitis is a common chronic allergic skin disease of humans and dogs. Among the molecules known to be present in the skin of dogs with atopic dermatitis is the cytokine Tumor Necrosis Factor (TNF-alpha), an upstream mediator that triggers a wide array of secondary inflammatory reactions. The goal of this study is to inject client-owned dogs diagnosed with naturally occuring atopic dermatitis with canine monoclonal antibody that blocks TNF-alpha, hoping to prevent inflammatory events leading to skin lesions and itch. Study participation is 6 weeks.


Owner Obligations:

We need owners of dogs to be able to commit to the following:

Financial Incentive:

$200 hospital credit for completed study. In addition, the study will cover investigational drug cost, exams and laboratory testing. Please see the contact below for more details.


NCSU Dermatology Service at 919-513-6543 or Berryman Hill at


Page last updated November 20, 2014